Catalyst Biosciences Company Profile (NASDAQ:CBIO)

About Catalyst Biosciences (NASDAQ:CBIO)

Catalyst Biosciences logoCatalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company's advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CBIO
  • CUSIP: 87611R30
  • Web: www.catalystbiosciences.com
Capitalization:
  • Market Cap: $17.85 million
  • Outstanding Shares: 4,260,000
Average Prices:
  • 50 Day Moving Avg: $4.45
  • 200 Day Moving Avg: $6.00
  • 52 Week Range: $3.64 - $28.50
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.98
  • P/E Growth: 0.03
Sales & Book Value:
  • Annual Revenue: $560,999.00
  • Price / Sales: 31.82
  • Book Value: $13.84 per share
  • Price / Book: 0.30
Profitability:
  • EBIDTA: ($18,690,000.00)
  • Net Margins: -2,961.29%
  • Return on Equity: -95.60%
  • Return on Assets: -39.65%
Debt:
  • Current Ratio: 1.87%
  • Quick Ratio: 1.87%
Misc:
  • Average Volume: 490,929 shs.
  • Beta: 1.67
  • Short Ratio: 0.7
 
Frequently Asked Questions for Catalyst Biosciences (NASDAQ:CBIO)

What is Catalyst Biosciences' stock symbol?

Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."

When did Catalyst Biosciences' stock split? How did Catalyst Biosciences' stock split work?

Shares of Catalyst Biosciences reverse split on the morning of Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 10th 2017. An investor that had 100 shares of Catalyst Biosciences stock prior to the reverse split would have 7 shares after the split.

How were Catalyst Biosciences' earnings last quarter?

Catalyst Biosciences, Inc. (NASDAQ:CBIO) released its quarterly earnings data on Thursday, May, 11th. The company reported ($4.57) EPS for the quarter, beating the Zacks' consensus estimate of ($5.14) by $0.57. The business had revenue of $0.27 million for the quarter. Catalyst Biosciences had a negative net margin of 2,961.29% and a negative return on equity of 95.60%. View Catalyst Biosciences' Earnings History.

Where is Catalyst Biosciences' stock going? Where will Catalyst Biosciences' stock price be in 2017?

3 brokers have issued 12-month price objectives for Catalyst Biosciences' shares. Their forecasts range from $10.00 to $52.50. On average, they anticipate Catalyst Biosciences' share price to reach $24.50 in the next twelve months. View Analyst Ratings for Catalyst Biosciences.

Who are some of Catalyst Biosciences' key competitors?

Who are Catalyst Biosciences' key executives?

Catalyst Biosciences' management team includes the folowing people:

  • Nassim Usman Ph.D., President, Chief Executive Officer, Director
  • Fletcher Payne, Chief Financial Officer
  • Andrew Hetherington, Vice President - Manufacturing Operations
  • Jeffrey Landau, Vice President - Business Development
  • Howard Levy Ph.D., Chief Medical Officer
  • Errol B. De Souza Ph.D., Director
  • Stephen Anthony Hill M.D., Director
  • Jeffrey Himawan Ph.D., Director
  • Augustine J. Lawlor, Director
  • John P. Richard, Director

Who owns Catalyst Biosciences stock?

Catalyst Biosciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include NEA Management Company LLC (1.02%). Company insiders that own Catalyst Biosciences stock include Fletcher Payne, Nassim Usman and Stephen A Hill. View Institutional Ownership Trends for Catalyst Biosciences.

How do I buy Catalyst Biosciences stock?

Shares of Catalyst Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catalyst Biosciences' stock price today?

One share of Catalyst Biosciences stock can currently be purchased for approximately $4.19.


MarketBeat Community Rating for Catalyst Biosciences (NASDAQ CBIO)
Community Ranking:  2.0 out of 5 ( )
Outperform Votes:  48 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  120
MarketBeat's community ratings are surveys of what our community members think about Catalyst Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Catalyst Biosciences (NASDAQ:CBIO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.50 (484.73% upside)

Analysts' Ratings History for Catalyst Biosciences (NASDAQ:CBIO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/12/2017Chardan CapitalInitiated CoverageBuy -> Buy$10.00HighView Rating Details
6/6/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$11.00LowView Rating Details
10/6/2016HC WainwrightReiterated RatingBuy$52.50N/AView Rating Details
6/30/2016Rodman & RenshawInitiated CoverageBuy$52.50N/AView Rating Details
(Data available from 7/26/2015 forward)

Earnings

Earnings History for Catalyst Biosciences (NASDAQ:CBIO)
Earnings by Quarter for Catalyst Biosciences (NASDAQ:CBIO)
Earnings History by Quarter for Catalyst Biosciences (NASDAQ CBIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/20173/31/2017($5.14)($4.57)$0.27 millionViewN/AView Earnings Details
3/8/201712/31/2016($5.63)($4.68)$0.10 million$0.10 millionViewN/AView Earnings Details
11/3/2016Q3($0.46)($0.40)$0.10 million$0.11 millionViewN/AView Earnings Details
8/4/2016Q216($0.31)($0.42)$0.10 million$0.11 millionViewN/AView Earnings Details
11/5/2014Q314($0.22)($0.14)$0.03 millionViewListenView Earnings Details
8/6/2014Q214($0.33)($0.24)$0.04 millionViewListenView Earnings Details
5/7/2014Q114($0.37)($0.44)$3.54 million$0.09 millionViewListenView Earnings Details
2/13/2014Q413($0.39)($0.40)$0.59 million$0.09 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.37)($0.37)$0.35 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.34)($0.24)$600.00 million$3.54 millionViewListenView Earnings Details
2/13/2013Q4 2012($0.31)($0.47)$0.83 million$0.59 millionViewListenView Earnings Details
11/6/2012Q312($0.39)($0.24)$0.87 million$0.77 millionViewN/AView Earnings Details
8/7/2012$0.39$0.43ViewN/AView Earnings Details
5/3/2012($0.25)$0.07ViewN/AView Earnings Details
2/21/2012($0.30)($0.29)ViewN/AView Earnings Details
11/1/2011($0.20)($0.27)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Catalyst Biosciences (NASDAQ:CBIO)
Current Year EPS Consensus Estimate: $-5.52 EPS
Next Year EPS Consensus Estimate: $-4.28 EPS

Dividends

Dividend History by Quarter for Catalyst Biosciences (NASDAQ CBIO)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/4/2015$0.578/12/20158/14/20158/19/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Catalyst Biosciences (NASDAQ:CBIO)
Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 5.57%
Insider Trades by Quarter for Catalyst Biosciences (NASDAQ:CBIO)
Institutional Ownership by Quarter for Catalyst Biosciences (NASDAQ:CBIO)
Insider Trades by Quarter for Catalyst Biosciences (NASDAQ:CBIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/17/2015Fletcher PayneCFOBuy10,000$2.00$20,000.00View SEC Filing  
12/17/2015Nassim UsmanCEOBuy4,000$2.00$8,000.00View SEC Filing  
12/17/2015Stephen A HillDirectorBuy5,000$2.03$10,150.00View SEC Filing  
12/5/2013Scott Sandellmajor shareholderSell1,000$5.13$5,130.00View SEC Filing  
11/21/2013M James Barrettmajor shareholderSell5,333$5.16$27,518.28View SEC Filing  
5/10/2013Julia R BrownDirectorBuy6,000$5.09$30,540.00View SEC Filing  
3/11/2013Stephen A HillCEOBuy20,000$4.43$88,600.00View SEC Filing  
11/16/2012Bvf Partners L P/IlMajor ShareholderBuy595,000$4.00$2,380,000.00View SEC Filing  
11/8/2012Bvf Partners L P/IlMajor ShareholderBuy72,429$4.03$291,888.87View SEC Filing  
11/2/2012Bvf Partners L P/IlMajor ShareholderBuy139,700$4.05$565,785.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Catalyst Biosciences (NASDAQ:CBIO)
Latest Headlines for Catalyst Biosciences (NASDAQ:CBIO)
Source:
DateHeadline
americanbankingnews.com logoOnconova Therapeutics (ONTX) versus Catalyst Biosciences (CBIO) Head to Head Review
www.americanbankingnews.com - July 17 at 4:28 PM
americanbankingnews.com logoAnalysts Anticipate Catalyst Biosciences, Inc. (NASDAQ:CBIO) to Post ($5.25) EPS
www.americanbankingnews.com - July 17 at 10:48 AM
finance.yahoo.com logoFinancial Milestone Achieved in Catalyst’s Subcutaneous Factor IX Program
finance.yahoo.com - July 6 at 6:12 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Catalyst Biosciences, Inc. (CBIO) to Post -$5.25 EPS
www.americanbankingnews.com - June 30 at 10:08 AM
finance.yahoo.com logoCatalyst Biosciences’ Factor IX Granted Orphan Drug Designation in Europe
finance.yahoo.com - June 28 at 4:58 PM
streetinsider.com logoCatalyst Biosciences (CBIO) Reports Achievement of Stable Normal Factor IX Blood Levels in a Preclinical Subcutaneous Dosing Model
www.streetinsider.com - June 27 at 9:26 PM
finance.yahoo.com logoCatalyst Biosciences Announces Achievement of Stable Normal Factor IX Blood Levels in a Preclinical Subcutaneous Dosing Model
finance.yahoo.com - June 26 at 4:48 PM
baystreet.ca logoCatalyst Covered by Chardan, Stock Springs
www.baystreet.ca - June 14 at 9:56 PM
finance.yahoo.com logoCatalyst Biosciences and ISU Abxis Complete Dosing of First Patient Cohort in Hemophilia B Clinical Trial
finance.yahoo.com - June 14 at 4:54 PM
americanbankingnews.com logoChardan Capital Initiates Coverage on Catalyst Biosciences, Inc. (CBIO)
www.americanbankingnews.com - June 12 at 6:06 PM
americanbankingnews.com logoLadenburg Thalmann Financial Services Initiates Coverage on Catalyst Biosciences Inc (CBIO)
www.americanbankingnews.com - June 11 at 2:38 PM
streetinsider.com logoCatalyst Biosciences (CBIO) Announces Presentations on Its Next-Generation Subcutaneous Hemophilia Product Candidates at ISTH Meeting
www.streetinsider.com - June 9 at 3:08 AM
finance.yahoo.com logoCatalyst Biosciences Announces Presentations on its Next-Generation Subcutaneous Hemophilia Product Candidates at the 2017 International Society on Thrombosis and Haemostasis (ISTH) Meeting
finance.yahoo.com - June 8 at 9:17 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Catalyst Biosciences Inc (CBIO) Will Announce Earnings of -$5.25 Per Share
www.americanbankingnews.com - June 6 at 8:21 AM
americanbankingnews.com logoCatalyst Biosciences Inc (CBIO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - June 5 at 7:32 PM
rttnews.com logoCatalyst Biosciences Inc. (CBIO) Is Climbing On Hemophilia B Treatment News
www.rttnews.com - May 31 at 9:15 PM
finance.yahoo.com logoCatalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe
finance.yahoo.com - May 31 at 10:19 AM
finance.yahoo.com logoCatalyst Biosciences, Inc. :CBIO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
finance.yahoo.com - May 24 at 12:54 PM
americanbankingnews.com logoCatalyst Biosciences Inc (CBIO) Issues Earnings Results
www.americanbankingnews.com - May 12 at 1:20 PM
finance.yahoo.com logoCatalyst Biosciences Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 11 at 4:46 PM
finance.yahoo.com logoCatalyst Biosciences reports 1Q loss
finance.yahoo.com - May 11 at 4:46 PM
americanbankingnews.com logo Analysts Expect Catalyst Biosciences Inc (CBIO) Will Announce Earnings of -$7.05 Per Share
www.americanbankingnews.com - May 10 at 4:26 PM
americanbankingnews.com logoCatalyst Biosciences Inc (CBIO) Short Interest Down 48.3% in April
www.americanbankingnews.com - May 7 at 7:36 AM
americanbankingnews.com logoCatalyst Biosciences (CBIO) Earning Somewhat Positive News Coverage, Study Finds
www.americanbankingnews.com - May 2 at 9:25 AM
americanbankingnews.com logoCatalyst Biosciences (CBIO) Earning Very Favorable Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 27 at 9:04 AM
americanbankingnews.com logoCatalyst Biosciences Inc (CBIO) Expected to Post Earnings of -$7.05 Per Share
www.americanbankingnews.com - April 27 at 1:13 AM
americanbankingnews.com logoCatalyst Biosciences (CBIO) Receives Daily News Impact Score of 0.31
www.americanbankingnews.com - April 21 at 2:09 PM
americanbankingnews.com logo Brokerages Expect Catalyst Biosciences Inc (CBIO) Will Post Earnings of -$7.05 Per Share
www.americanbankingnews.com - April 19 at 6:19 PM
americanbankingnews.com logoCatalyst Biosciences (CBIO) Receiving Very Positive Press Coverage, Report Shows
www.americanbankingnews.com - April 17 at 12:27 PM
americanbankingnews.com logoCatalyst Biosciences (CBIO) Getting Positive Press Coverage, Analysis Shows
www.americanbankingnews.com - April 14 at 9:14 AM
finance.yahoo.com logoCatalyst Biosciences Announces Closing of a $20.7 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
finance.yahoo.com - April 12 at 4:10 PM
americanbankingnews.com logoCatalyst Biosciences Inc (CBIO) Upgraded by Zacks Investment Research to Strong-Buy
www.americanbankingnews.com - April 11 at 8:30 PM
finance.yahoo.com logoKey Milestone Reached in Catalyst’s Subcutaneous Factor IX Program
finance.yahoo.com - April 11 at 10:06 AM
finance.yahoo.com logoCatalyst Biosciences Sinks After Pricing Secondary Offering
finance.yahoo.com - April 7 at 4:10 PM
finance.yahoo.com logoCatalyst Biosciences Announces Pricing of $18 Million Underwritten Public Offering
finance.yahoo.com - April 7 at 8:51 AM
finance.yahoo.com logoToday's Research Reports on Biotech Stocks to Watch: Catalyst Biosciences and Pernix Therapeutics
finance.yahoo.com - March 30 at 4:35 PM
finanznachrichten.de logoGainers & Losers Of Mar.28: CBIO, AKER, IMMY, HTGM, PAVM...
www.finanznachrichten.de - March 29 at 12:28 PM
streetinsider.com logoCatalyst Biosciences (CBIO) Announces IND Approval in South Korea for CB 2679d/ISU304
www.streetinsider.com - March 29 at 12:28 PM
rttnews.com logoCatalyst Biosciences Inc. (CBIO) Spiked Higher After Korean Approval
www.rttnews.com - March 29 at 12:28 PM
nasdaq.com logoCatalyst Biosciences Announces IND Approval in South Korea for Next-Generation Subcutaneous Factor IX Program
www.nasdaq.com - March 28 at 12:52 PM
rttnews.com logoCatalyst Biosciences Inc. (CBIO) Is Soaring After South Korean Approval
www.rttnews.com - March 28 at 12:52 PM
finance.yahoo.com logoWhy Catalyst Bio Nearly Tripled
finance.yahoo.com - March 28 at 12:52 PM
investorplace.com logoWhy Catalyst Biosciences Inc (CBIO) Stock Tripled on Tuesday
investorplace.com - March 28 at 10:52 AM
finance.yahoo.com logoCATALYST BIOSCIENCES, INC. Financials
finance.yahoo.com - March 14 at 4:04 PM
us.rd.yahoo.com logoCatalyst Biosciences Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
us.rd.yahoo.com - March 8 at 4:54 PM
msn.com logoCatalyst Biosciences (CBIO) Win Streak Continues
www.msn.com - March 1 at 9:59 AM
finance.yahoo.com logoCatalyst Biosciences Announces Promotion of Andrew Hetherington to SVP of Technical Operations
finance.yahoo.com - February 16 at 8:59 AM
globenewswire.com logoCatalyst Biosciences Highlights Hemophilia Clinical Development Plans at the 19th Annual BIO CEO & Investor Conference
globenewswire.com - February 14 at 4:51 PM
biz.yahoo.com logoSplits Calendar: Catalyst Biosciences splits before market open today (1:15 ratio)
biz.yahoo.com - February 13 at 4:46 PM
streetinsider.com logoCatalyst Biosciences (CBIO) Plans 1-for-15 Reverse Stock Split
www.streetinsider.com - February 11 at 4:16 PM

Social

Chart

Catalyst Biosciences (CBIO) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff